glp-1 cardiovascular outcomes news The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 Receptor Agonist Therapy With

Track liver enzymes as standard practice Measure body composition via DEXA to quantify your actual results, not just the number on the scale

Oral Wegovy (Semaglutide Tablet): An FDA-approved oral GLP-1 receptor agonist that provides a non-injection alternative, using semaglutide to support sustainable weight loss

doi: 10.1159/000509846

But one active clinical trial, registered as NCT07092605 on ClinicalTrials.gov, is now specifically studying the effectiveness of microdosed GLP-1 receptor agonists for improving health and quality of life in patients who do not meet traditional prescribing criteria

Someone carrying extra weight who still runs half marathons, with normal blood sugar, normal labs, and good energy, has what the commission calls preclinical obesity: a state worth watching, with elevated future risk, but not necessarily one that demands aggressive treatment today